Correspondence on “Exposure to Novel Brominated Flame Retardants and Organophosphate Esters and Associations with Thyroid Cancer Risk: A Case–Control Study in Eastern China”
Environmental Science & Technology · 2024
DOI: 10.1021/acs.est.3c10757 ↗Kurz gefasst
Leserbrief in der Zeitschrift Environmental Science & Technology, 2024. Verfasst von Zeinab Bahrami und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Preventive Services, Graduate School of Medicine, Kyoto University, Kyoto 606-8303, Japan. Hauptthemen laut MEDLINE: Flame Retardants, Thyroid Neoplasms. Die Arbeit nennt 3 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Preventive Services, Graduate School of Medicine, Kyoto University, Kyoto 606-8303, Japan.
- Department of Health and Environmental Sciences, Graduate School of Medicine, Kyoto University, Kyoto 606-8303, Japan.
ORCID-Profile: Zhaoqing Lyu, Kouji H Harada
Zitieren
APA
Bahrami, Z., Fan, M., Juraev, J., Lyu, Z., & Harada, K. H. (2024). Correspondence on “Exposure to Novel Brominated Flame Retardants and Organophosphate Esters and Associations with Thyroid Cancer Risk: A Case–Control Study in Eastern China”. Environmental Science & Technology. https://doi.org/10.1021/acs.est.3c10757
Vancouver
Bahrami Z, Fan M, Juraev J, Lyu Z, Harada KH. Correspondence on “Exposure to Novel Brominated Flame Retardants and Organophosphate Esters and Associations with Thyroid Cancer Risk: A Case–Control Study in Eastern China”. Environmental Science & Technology. 2024. doi:10.1021/acs.est.3c10757
BibTeX
@article{Bahrami2024,
author = {Bahrami, Zeinab and Fan, Menglin and Juraev, Jasur and Lyu, Zhaoqing and Harada, Kouji H},
title = {Correspondence on “Exposure to Novel Brominated Flame Retardants and Organophosphate Esters and Associations with Thyroid Cancer Risk: A Case–Control Study in Eastern China”},
journal = {Environmental Science & Technology},
year = {2024},
doi = {10.1021/acs.est.3c10757}
}
EUVIMED